1 min read
Add as a preferred source on GoogleRhythm Pharmaceuticals Expects to Dose First Phase III Patients in January
The company committed $350 million to a royalty buy-down. CEO David Meeker cited $92 million in third-quarter revenue and called the U.S. launch an “excellent start.”
Rhythm Pharmaceuticals expects to begin dosing the first patients in January in a Phase III trial of bivamelagon for HO. The company also committed $350 million to a royalty buy-down.
Chairman, President and CEO David Meeker cited third-quarter revenue of $92 million and described the U.S. launch as an “excellent start.”
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.